
WHAT IS CLAIMED IS:

1. A compound of formula (III)



(III)

wherein R^2 is hydroxy-C_{1-6}alkyl,

or a stereoisomer or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein R^2 is hydroxyethyl or hydroxypropyl, or a stereoisomer or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1, wherein R^2 is 2-hydroxyethyl, 2-hydroxypropyl, 2-hydroxy-1-methyl-ethyl, or 2-hydroxy-1-methyl-propyl, or a stereoisomer or a pharmaceutically acceptable salt thereof.




4. The compound of claim 1 or 3, wherein R^2 is 2-hydroxyethyl, or a stereoisomer or a pharmaceutically acceptable salt thereof.




5. The compound of claim 1 or 3, wherein R^2 is 2-hydroxypropyl, or a stereoisomer or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 or 3, wherein R^2 is 2-hydroxy-1-methyl-ethyl, or a stereoisomer or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 or 3, wherein R^2 is 2-hydroxy-1-methyl-propyl, or a stereoisomer or a pharmaceutically acceptable salt thereof.


8. The compound of claim 1, selected from:


;

;

;


;

; and

;


or a stereoisomer or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 or 8, wherein the compound is




or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 or 8, wherein the compound is




or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 or 8, wherein the compound is




or a stereoisomer or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1 or 8, wherein the compound is




or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1 or 8, wherein the compound is



or a pharmaceutically acceptable salt thereof.

14. The compound of claim 1 or 8, wherein the compound is



or a stereoisomer or a pharmaceutically acceptable salt thereof.

15. Use of a compound of any of claims 1-14, or a stereoisomer or pharmaceutically acceptable salt thereof in the manufacture of a medicament for preventing, treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

16. The use of claim 15, wherein the disease or condition is cancer, stroke, diabetes, hepatomegaly, cardiovascular disease, multiple sclerosis, Alzheimer's disease, cystic fibrosis, viral disease, autoimmune diseases, atherosclerosis, restenosis, psoriasis, rheumatoid arthritis, inflammatory bowel disease, asthma, allergic disorders, inflammation, neurological disorders, a hormone-related disease, conditions associated with organ transplantation (e.g., transplant rejection), immunodeficiency disorders, destructive bone disorders, proliferative disorders, infectious diseases, conditions associated with cell death, thrombin-induced platelet aggregation, liver disease, pathologic immune conditions involving T cell activation, CNS disorders or a myeloproliferative disorder.

17. A pharmaceutical composition comprising a compound of any of claims 1-14, or a stereoisomer or pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition comprises microparticles of the compound suitable for inhaled delivery.

18. The pharmaceutical composition of claim 17, wherein the microparticles are prepared by spray-drying, freeze-drying or micronisation.

19. The pharmaceutical composition of claims 17 or 18, further comprising an excipient.

20. A compound of any of claims 1-14 or a stereoismer or pharmaceutically acceptable salt thereof for use in the treatment of an inflammatory disease.

21. Use of a compound of any of claims 1-14 or a stereoismer or pharmaceutically acceptable salt thereof for preparation of a medicament for treatment of an inflammatory disease.

22. Use of a compound of any of claims 1-14 or a stereoismer or pharmaceutically acceptable salt thereof for preparation of a medicament for treatment of an inflammatory disease, wherein the inflammatory disease is asthma.